| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,540 |
2,287 |
$190K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,035 |
1,033 |
$99K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
530 |
491 |
$54K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
892 |
868 |
$32K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
199 |
199 |
$28K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,526 |
1,470 |
$22K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
530 |
515 |
$14K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
381 |
364 |
$6K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
12 |
12 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
32 |
32 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
14 |
14 |
$890.12 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
97 |
95 |
$197.90 |
| 87807 |
|
13 |
12 |
$151.45 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
86 |
86 |
$84.04 |
| J7510 |
Prednisolone oral, per 5 mg |
71 |
70 |
$20.58 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
22 |
22 |
$0.85 |